KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Adaptive Biotechnologies (ADPT) Operating Margin: 2018-2025

Historic Operating Margin for Adaptive Biotechnologies (ADPT) over the last 8 years, with Sep 2025 value amounting to 10.95%.

  • Adaptive Biotechnologies' Operating Margin rose 8122.00% to 10.95% in Q3 2025 from the same period last year, while for Sep 2025 it was -30.93%, marking a year-over-year increase of 8176.00%. This contributed to the annual value of -90.83% for FY2024, which is 4250.00% up from last year.
  • Adaptive Biotechnologies' Operating Margin amounted to 10.95% in Q3 2025, which was up 125.75% from -42.52% recorded in Q2 2025.
  • In the past 5 years, Adaptive Biotechnologies' Operating Margin registered a high of 10.95% during Q3 2025, and its lowest value of -621.01% during Q2 2023.
  • Its 3-year average for Operating Margin is -138.01%, with a median of -109.56% in 2024.
  • As far as peak fluctuations go, Adaptive Biotechnologies' Operating Margin plummeted by 50,076bps in 2023, and later spiked by 51,146bps in 2024.
  • Adaptive Biotechnologies' Operating Margin (Quarterly) stood at -162.39% in 2021, then skyrocketed by 9,140bps to -70.99% in 2022, then slumped by 8,423bps to -155.22% in 2023, then skyrocketed by 8,393bps to -71.30% in 2024, then surged by 8,122bps to 10.95% in 2025.
  • Its Operating Margin was 10.95% in Q3 2025, compared to -42.52% in Q2 2025 and -56.45% in Q1 2025.